NCT06331455View on ClinicalTrials.gov

Treatment of Pulmonary SUlcus, Pancoast and Chest Wall Non-small Cell Lung Cancer Employing Radiation, Immuno-oncology and Resection

PHASE2RecruitingINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

May 22, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

April 30, 2026

Conditions
Lung Cancer PatientsNon-small Cell Lung Cancer (NSCLC)
Interventions
DRUG

Durvalumab

Two doses of durvalumab (1500 mg IV)

RADIATION

Non-ablative oligofractionated radiation (NORT)

12 Gy of Radiation in 3 fractions

Trial Locations (1)

Unknown

RECRUITING

Toronto General Hospital, Toronto

Sponsors

Collaborators (1)

Ozmosis Research Inc.
All Listed Sponsors
collaborator

Ozmosis Research Inc.

INDUSTRY

lead

Marc de Perrot

OTHER